CL2011000496A1 - Proceso para la preparacion de [1s-[1alfa,2alfa,3beta(1s*,2r*),5beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3h-1,2,3-triazolo[4,5d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol basado en el uso de sales de oxalatos; y uno de los compuestos intermediarios considerados. - Google Patents

Proceso para la preparacion de [1s-[1alfa,2alfa,3beta(1s*,2r*),5beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3h-1,2,3-triazolo[4,5d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol basado en el uso de sales de oxalatos; y uno de los compuestos intermediarios considerados.

Info

Publication number
CL2011000496A1
CL2011000496A1 CL2011000496A CL2011000496A CL2011000496A1 CL 2011000496 A1 CL2011000496 A1 CL 2011000496A1 CL 2011000496 A CL2011000496 A CL 2011000496A CL 2011000496 A CL2011000496 A CL 2011000496A CL 2011000496 A1 CL2011000496 A1 CL 2011000496A1
Authority
CL
Chile
Prior art keywords
5beta
3beta
1alpha
cyclopropylamino
propylthio
Prior art date
Application number
CL2011000496A
Other languages
English (en)
Inventor
Martin Hans Bohlin
Mikaela Recknagel
Rhony Aufdenblatten
Helena Hellström
Peter W Johansson
Ulf G Larsson
Ursula Heredera De Weiss Andreas Weiss
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42005334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2011000496A1 publication Critical patent/CL2011000496A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Procedimiento de preparación de [1s-[1alfa,2alfa,3beta(1s*,2r*),5beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3h-1,2,3-triazolo[5,4d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol; compuesto intermediario; y procedimiento de preparación de compuestos intermediarios.
CL2011000496A 2008-09-09 2011-03-08 Proceso para la preparacion de [1s-[1alfa,2alfa,3beta(1s*,2r*),5beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3h-1,2,3-triazolo[4,5d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol basado en el uso de sales de oxalatos; y uno de los compuestos intermediarios considerados. CL2011000496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9534108P 2008-09-09 2008-09-09

Publications (1)

Publication Number Publication Date
CL2011000496A1 true CL2011000496A1 (es) 2011-08-26

Family

ID=42005334

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000496A CL2011000496A1 (es) 2008-09-09 2011-03-08 Proceso para la preparacion de [1s-[1alfa,2alfa,3beta(1s*,2r*),5beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3h-1,2,3-triazolo[4,5d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol basado en el uso de sales de oxalatos; y uno de los compuestos intermediarios considerados.

Country Status (20)

Country Link
US (1) US8563755B2 (es)
EP (1) EP2340252B1 (es)
JP (1) JP5656837B2 (es)
KR (1) KR101669297B1 (es)
CN (1) CN102149716A (es)
AU (1) AU2009292269B2 (es)
BR (1) BRPI0918038B1 (es)
CA (1) CA2734454C (es)
CL (1) CL2011000496A1 (es)
DK (1) DK2340252T3 (es)
ES (1) ES2558843T3 (es)
HK (1) HK1159103A1 (es)
HR (1) HRP20160018T1 (es)
IL (1) IL211191A (es)
MX (1) MX2011002505A (es)
MY (1) MY156796A (es)
RU (1) RU2509082C2 (es)
SG (1) SG196805A1 (es)
SI (1) SI2340252T1 (es)
WO (1) WO2010030224A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
EP3135675A1 (en) 2009-07-27 2017-03-01 Auspex Pharmaceuticals, Inc. Deuterated derivatives of ticagrelor for medical use
US8859769B2 (en) 2010-02-16 2014-10-14 Actavis Group Ptc Ehf Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US20130150577A1 (en) 2010-04-20 2013-06-13 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
CN103003231A (zh) 2010-06-30 2013-03-27 阿特维斯集团公司 制备苯基环丙基胺衍生物的新方法及其用于制备替卡格雷的用途
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
MX2013007115A (es) 2010-12-20 2014-02-10 Actavis Group Ptc Ehf Procesos novedosos para preparar derivados de triazolo[4, 5 - d] pirimidina e intermediarios de los mismos.
US9056838B2 (en) 2011-04-06 2015-06-16 Teva Pharmaceutical Industries Ltd. Intermediates and processes for preparing Ticagrelor
EP2721018A1 (en) 2011-06-15 2014-04-23 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
HUE031673T2 (en) 2011-09-14 2017-07-28 Lek Pharmaceuticals Synthesis of triazolopyrimidine compounds
EP2570405A1 (en) 2011-09-14 2013-03-20 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
IN2014KN01062A (es) * 2011-10-27 2015-10-09 Lek Pharmaceuticals
EP2586773A1 (en) 2011-10-27 2013-05-01 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
WO2013079589A1 (en) 2011-11-30 2013-06-06 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
EP2607355A1 (en) * 2011-12-23 2013-06-26 LEK Pharmaceuticals d.d. Synthesis of triazolopyrimidine compounds
CA2859580A1 (en) * 2011-12-23 2013-06-27 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2628721A1 (en) 2012-02-20 2013-08-21 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid
EP2834247A4 (en) * 2012-04-05 2016-03-30 Reddys Lab Ltd Dr PREPARATION OF TICAGRELOR
EP2870155B1 (en) * 2012-07-04 2016-08-24 LEK Pharmaceuticals d.d. Ticagrelor adducts with divalent metal salts
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014102830A1 (en) * 2012-12-31 2014-07-03 Megafine Pharma (P) Ltd. A process for preparation of ticagrelor and intermediates thereof
CN103965198A (zh) * 2013-02-05 2014-08-06 郝聪梅 替卡格雷的中间体及其制备方法以及利用该中间体制备替卡格雷的方法
CN104045620B (zh) * 2013-03-12 2017-05-10 博瑞生物医药（苏州）股份有限公司 一种替卡格雷中间体的制备方法
CN107573333B (zh) * 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
CN106496234B (zh) * 2013-06-03 2019-08-30 杭州领业医药科技有限公司 结晶形态的三唑[4,5-d]嘧啶化合物及其制备方法和用途
CN104230818B (zh) * 2013-06-06 2018-01-12 郝聪梅 替卡格雷中间体的改进制备方法
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
CN103275087A (zh) * 2013-06-28 2013-09-04 南京工业大学 一种三氮唑并嘧啶类衍生物及其制备方法
CN104059069B (zh) * 2013-08-22 2016-08-10 北京康立生医药技术开发有限公司 一种替卡格雷的制备方法
WO2015037016A2 (en) * 2013-09-10 2015-03-19 Laurus Labs Private Limited An improved process for the preparation of ticagrelor and intermediates thereof
CN104592237A (zh) * 2013-10-31 2015-05-06 徐州万邦金桥制药有限公司 一种抗凝血药替格瑞洛的合成方法
CN103588712B (zh) * 2013-11-08 2016-06-08 南京欧信医药技术有限公司 一种嘧啶类化合物及其制备方法、和应用
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN103992277A (zh) * 2014-05-16 2014-08-20 苏州天马精细化学品股份有限公司 一种替卡格雷中间体4,6-二氯-5-氨基-2-丙硫基嘧啶的制备方法
US10011605B2 (en) 2014-06-18 2018-07-03 Flamma Spa Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
CN104311560B (zh) * 2014-09-16 2017-04-26 北京红太阳药业有限公司 一种替格瑞洛的制备方法
CN104788458A (zh) * 2015-03-21 2015-07-22 北京工业大学 一种替格瑞洛的制备方法
CN105294573B (zh) * 2015-06-16 2018-07-10 厦门医学院 一种合成4,6-二氯-2-(丙硫基)-5-氨基嘧啶的方法
CN105153167B (zh) * 2015-09-06 2017-09-19 惠州信立泰药业有限公司 一种替格瑞洛结晶及含有该结晶的药物组合物
CN105237540B (zh) * 2015-09-21 2017-10-03 南京正大天晴制药有限公司 一种替格瑞洛有关物质的制备方法、检测方法及用途
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
CN105669681A (zh) * 2016-04-11 2016-06-15 成都华宇制药有限公司 一种替格瑞洛的合成方法
CN106866682A (zh) * 2017-04-14 2017-06-20 上海华源医药科技发展有限公司 一种适用于替格瑞洛工业化生产的工艺
CA3138307A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
CN115160320B (zh) * 2022-06-27 2024-05-07 南通常佑药业科技有限公司 一种手性嘧啶并三唑类替格瑞洛的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
AU4555797A (en) 1996-09-23 1998-04-17 Novartis Ag Process for the preparation of substituted aromatic amino compounds
US5962741A (en) 1996-11-19 1999-10-05 Novartis Ag Process for the production of aromatic halogen-amino compounds
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TR200002380T2 (tr) * 1998-02-17 2001-03-21 Astrazeneca Uk Limited Yeni triazolo (4,5-d) pirimidin bileşikleri
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
TWI290549B (en) 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
WO2002091988A2 (en) * 2001-05-10 2002-11-21 Aventis Pharma Deutschland Gmbh Novel processes for the preparation of adenosine compounds and intermediates thereto
EP1574508A1 (de) * 2004-01-30 2005-09-14 Lonza AG Verfahren zur Herstellung von Acetalen und Ketalen von 3-Amino-5-(hydroxymethyl)-cyclopentan-1,2-diolen, sowie deren Derivaten und Salzen
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
GB0615619D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab Chemical process for preparation of intermediates

Also Published As

Publication number Publication date
JP2012502024A (ja) 2012-01-26
BRPI0918038B1 (pt) 2021-07-13
EP2340252A4 (en) 2012-08-01
DK2340252T3 (en) 2016-01-18
CA2734454A1 (en) 2010-03-18
HRP20160018T1 (hr) 2016-02-12
JP5656837B2 (ja) 2015-01-21
CN102149716A (zh) 2011-08-10
MX2011002505A (es) 2011-04-07
US8563755B2 (en) 2013-10-22
ES2558843T3 (es) 2016-02-09
KR101669297B1 (ko) 2016-10-25
AU2009292269B2 (en) 2012-11-01
IL211191A (en) 2015-07-30
SG196805A1 (en) 2014-02-13
EP2340252A1 (en) 2011-07-06
SI2340252T1 (sl) 2016-02-29
BRPI0918038A2 (pt) 2015-08-04
RU2011109436A (ru) 2012-10-20
EP2340252B1 (en) 2015-11-11
AU2009292269A1 (en) 2010-03-18
MY156796A (en) 2016-03-31
CA2734454C (en) 2016-09-13
KR20110063460A (ko) 2011-06-10
RU2509082C2 (ru) 2014-03-10
WO2010030224A1 (en) 2010-03-18
HK1159103A1 (zh) 2012-07-27
US20120101274A1 (en) 2012-04-26
IL211191A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CL2011000496A1 (es) Proceso para la preparacion de [1s-[1alfa,2alfa,3beta(1s*,2r*),5beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3h-1,2,3-triazolo[4,5d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol basado en el uso de sales de oxalatos; y uno de los compuestos intermediarios considerados.
MX343702B (es) Proceso para preparacion de ciclopropilaminas opticamente activas.
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
CL2013001609A1 (es) Uso de compuestos fenil o piridin sustituidos como intermediarios para la preparacion de un compuesto conjugado de dimeros de pirrolo[1,4]benzodiazepina (pbd) (divisional de la solicitud 489-2012).
CL2014001309A1 (es) Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras.
BRPI0703133A2 (pt) composição catalisadora, composição, método de fabricação de um poliuretano, método para preparação de uma espuma de poliuretano, e composto
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
CL2011002955A1 (es) Compuestos derivados de 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octanonitrilo o heptanonitrilo o sus sales, como inhibidores de jak; procedimiento de preparacion; composicion farmaceutica que los comprende; utiles para el tratamiento de trastornos autoinmunes, cancer, entre otras enfermedades.
ECSP077336A (es) Control de parásitos en animales mediante el uso de nuevos derivados de trifluorometansulfonanilida oxima éter
CL2008000905A1 (es) Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
GT200600138A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
DOP2006000202A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
CU24292B1 (es) N-(6-((2r, 3s)- 3,4- dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3- metilacetidina-1-sulfonamida como modulador del receptor de quimiocina
EA201070853A1 (ru) Кристаллический (r)-2-(4-циклопропансульфонилфенил)-n-пиразин-2-ил-3-(тетрагидропиран-4-ил)пропионамид
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método
BRPI0511554A (pt) composto ou um sal ou pró-droga farmaceuticamente aceitável do mesmo, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou de um sal farmaceuticamente aceitável, ou de um éster hidrolisável in vivo do mesmo, composição farmacêutica, e, processo para a preparação de um composto ou de um sal farmaceuticamente aceitável, ou de um éster hidrolisável in vivo do mesmo
DOP2011000017A (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
EA200701867A1 (ru) Хинолиноновые соединения в качестве агонистов рецептора 5-ht
BRPI0520579B8 (pt) composto, processo para a preparação de um composto e composição farmacêutica
CL2007002637A1 (es) Compuestos derivados de acido 2-fenoxinicotinico; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de dislipidemias, arteriosclerosis e insuficiencia cardiaca.
AR083755A1 (es) Formas solidas del acido (s)-2-amino-3-(4-(-2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoico
ES2522317T3 (es) Ticagrelor para tratamiento de aneurismas aórticos abdominales